US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8928874D0
(en)
*
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
EP1400536A1
(de)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Verfahren zur Herstellung humanisierter Antikörper
|
EP0861893A3
(de)
|
1991-09-19 |
1999-11-10 |
Genentech, Inc. |
Hohe expression von immunglobulinen
|
WO1993016193A1
(en)
*
|
1992-02-14 |
1993-08-19 |
Suntory Limited |
Cell adhesion inhibiting antibody and cell adhesion inhibitor containing the same
|
GB9215540D0
(en)
*
|
1992-07-22 |
1992-09-02 |
Celltech Ltd |
Protein expression system
|
GB9215541D0
(en)
*
|
1992-07-22 |
1992-09-02 |
Celltech Ltd |
Protein expression system
|
GB9215550D0
(en)
*
|
1992-07-22 |
1992-09-02 |
Celltech Ltd |
Protein expression system
|
DE4225853A1
(de)
*
|
1992-08-05 |
1994-02-10 |
Behringwerke Ag |
Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
|
WO1994013805A1
(en)
*
|
1992-12-10 |
1994-06-23 |
Celltech Limited |
Humanised antibodies directed against a33 antigen
|
GB9324807D0
(en)
*
|
1993-12-03 |
1994-01-19 |
Cancer Res Campaign Tech |
Tumour antibody
|
WO1996002576A1
(fr)
*
|
1994-07-13 |
1996-02-01 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humain reconstitue contre l'interleukine-8 humaine
|
US5874540A
(en)
*
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
DE19518769C2
(de)
*
|
1995-05-22 |
1997-04-17 |
Gsf Forschungszentrum Umwelt |
Inter-LINE-PCR
|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
DK0929578T3
(da)
*
|
1996-02-09 |
2003-08-25 |
Abbott Lab Bermuda Ltd |
Humane antistoffer, der binder human TNFalfa
|
JP2000510692A
(ja)
|
1996-05-04 |
2000-08-22 |
ゼネカ リミテッド |
Ceaに対するモノクローナル抗体、その抗体を含む結合体、およびadeptシステムにおけるそれらの治療的使用
|
UA76934C2
(en)
*
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
CA2289665C
(en)
|
1997-06-13 |
2005-08-09 |
Genentech, Inc. |
Protein recovery by chromatography followed by filtration upon a charged layer
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
EP1056859A1
(de)
*
|
1998-02-25 |
2000-12-06 |
The Dow Chemical Company |
Humanisierte monoklonale antikörper mit hoher affinität gegen cea
|
GB9818915D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Ks Biomedix Ltd |
Antibodies
|
US20020068066A1
(en)
*
|
1999-08-20 |
2002-06-06 |
Wenyuan Shi |
Method for the treatment and prevention of dental caries
|
GB0001448D0
(en)
|
2000-01-21 |
2000-03-08 |
Novartis Ag |
Organic compounds
|
WO2001081401A1
(fr)
|
2000-04-21 |
2001-11-01 |
Fuso Pharmaceutical Industries, Ltd. |
Nouvelles collectines
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
AU2000270698A1
(en)
*
|
2000-08-24 |
2002-03-04 |
Regents Of The Universtiy Of California |
Immunologic method for the prevention of dental caries
|
DZ3494A1
(fr)
|
2001-01-05 |
2002-07-11 |
Pfizer |
Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline
|
WO2002062850A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
AU2002307554A1
(en)
*
|
2001-04-23 |
2002-11-05 |
Abgenix, Inc. |
Anti-alpha3(iv)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
GB0124317D0
(en)
|
2001-10-10 |
2001-11-28 |
Celltech R&D Ltd |
Biological products
|
US8361464B2
(en)
*
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
AU2003220525A1
(en)
*
|
2002-03-29 |
2003-10-20 |
Abgenix, Inc. |
Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
|
CN102793921A
(zh)
|
2002-04-09 |
2012-11-28 |
比奥根艾迪克Ma公司 |
用于治疗tweak 相关病症的方法
|
US20040009172A1
(en)
*
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US7232888B2
(en)
|
2002-07-01 |
2007-06-19 |
Massachusetts Institute Of Technology |
Antibodies against tumor surface antigens
|
EP2298810A3
(de)
*
|
2002-07-19 |
2011-08-03 |
Abbott Biotechnology Ltd |
Behandlung von Erkrankungen im Zusammenhang mit TNF-alpha
|
EA200500330A1
(ru)
*
|
2002-08-10 |
2006-06-30 |
Йейл Юниверсити |
Антагонисты nogo рецепторов
|
CA2501616C
(en)
|
2002-10-08 |
2015-05-12 |
Immunomedics, Inc. |
Antibody therapy
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
DE60332483D1
(de)
|
2002-11-15 |
2010-06-17 |
Novartis Vaccines & Diagnostic |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
EP1615654A2
(de)
*
|
2003-04-16 |
2006-01-18 |
Yale University |
Nogo-rezeptor antagonisten zur behandlung von krankheiten die mit amyloidplaque in verbindung stehen
|
AU2004234364A1
(en)
*
|
2003-04-24 |
2004-11-11 |
Lisette Acevedo |
Nogo-B, a regulator of endothelial cell function and vessel remodeling
|
BRPI0416141B8
(pt)
*
|
2003-11-01 |
2021-05-25 |
Biovation Ltd |
anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
|
PL2311873T3
(pl)
|
2004-01-07 |
2019-01-31 |
Novartis Vaccines And Diagnostics, Inc. |
Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania
|
JP4315982B2
(ja)
|
2004-01-09 |
2009-08-19 |
ファイザー インコーポレイティッド |
MAdCAMに対する抗体
|
US7875598B2
(en)
*
|
2004-03-04 |
2011-01-25 |
The Regents Of The University Of California |
Compositions useful for the treatment of microbial infections
|
WO2005090406A2
(en)
|
2004-03-12 |
2005-09-29 |
Vasgene Therapeutics, Inc. |
Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
AU2005291486A1
(en)
*
|
2004-10-01 |
2006-04-13 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Novel antibodies directed to the mammalian EAG1 ion channel protein
|
US20060083741A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Hoffman Rebecca S |
Treatment of respiratory syncytial virus (RSV) infection
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
CA2589860A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
ES2716874T3
(es)
|
2005-03-23 |
2019-06-17 |
Genmab As |
Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
|
WO2006124627A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Biogen Idec Ma Inc. |
Methods of treating conditions involving neuronal degeneration
|
CA2903138A1
(en)
|
2005-05-16 |
2006-11-23 |
Abbvie Biotechnology Ltd. |
Use of tnfa inhibitor for treatment of erosive polyarthritis
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
WO2007016240A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
Use of antibody to m-csf
|
WO2007016285A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
US20070041905A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
PL1976880T3
(pl)
*
|
2005-12-21 |
2017-01-31 |
Amgen Research (Munich) Gmbh |
Kompozycje farmaceutyczne odporne na rozpuszczalny cea
|
EP1976885B1
(de)
*
|
2005-12-21 |
2014-12-03 |
Amgen Research (Munich) GmbH |
Pharmazeutische antikörperzusammensetzungen mit resistenz gegenüber löslichem cea
|
EP1981902B1
(de)
|
2006-01-27 |
2015-07-29 |
Biogen MA Inc. |
Nogo-rezeptorantagonisten
|
EP2010569A4
(de)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
Für gastrin spezifische humane antikörper, materialien und methoden
|
SG170837A1
(en)
*
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
EP2007426A4
(de)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
US9399061B2
(en)
*
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
WO2009017467A1
(en)
|
2007-07-27 |
2009-02-05 |
Elan Pharma International Limited |
Treatment of amyloidogenic diseases
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
EP2021030A2
(de)
*
|
2006-04-21 |
2009-02-11 |
Amgen, Inc. |
Puffermittel für biopharmazeutische formulierungen
|
NO346945B1
(no)
|
2006-06-30 |
2023-03-13 |
Novo Nordisk As |
Anti-NKG2A-antistoffer og anvendelser derav
|
ES2452067T3
(es)
*
|
2006-08-04 |
2014-03-31 |
Novartis Ag |
Anticuerpo específico para EPHB3 y usos del mismo
|
PT2059535E
(pt)
*
|
2006-08-18 |
2014-01-29 |
Novartis Ag |
Anticorpos específicos do prlr e suas utulizações
|
CA2661634C
(en)
|
2006-09-06 |
2017-03-28 |
The Regents Of The University Of California |
Selectively targeted antimicrobial peptides and the use thereof
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
AU2007294909A1
(en)
|
2006-09-08 |
2008-03-20 |
Amgen Inc. |
IL-1 family variants
|
DK2081595T3
(da)
|
2006-09-26 |
2019-07-15 |
Genmab As |
Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
WO2008045373A2
(en)
*
|
2006-10-06 |
2008-04-17 |
Amgen Inc. |
Stable antibody formulations
|
EP2094247B1
(de)
*
|
2006-10-20 |
2022-06-29 |
Amgen Inc. |
Stabile polypeptid-formulierungen
|
US8394927B2
(en)
|
2006-11-03 |
2013-03-12 |
U3 Pharma Gmbh |
FGFR4 antibodies
|
KR20140119831A
(ko)
|
2006-12-07 |
2014-10-10 |
노파르티스 아게 |
Ephb3에 대한 길항제 항체
|
EP3124045A3
(de)
|
2006-12-20 |
2017-05-03 |
Xoma (Us) Llc |
Behandlung von il-1-beta-bedingten erkrankungen
|
ES2748526T3
(es)
*
|
2006-12-21 |
2020-03-17 |
Amgen Inc |
Formulaciones tamponadas estables que contienen polipéptidos
|
NZ578816A
(en)
|
2007-02-02 |
2012-06-29 |
Biogen Idec Inc |
Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
|
TW200900420A
(en)
*
|
2007-02-02 |
2009-01-01 |
Amgen Inc |
Hepcidin, hepcidin antagonists and methods of use
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
EP2014681A1
(de)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Neue Antikörper zur Hemmung der C-Met-Dimerisation und Verwendungen davon
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
ES2556214T3
(es)
|
2007-11-12 |
2016-01-14 |
U3 Pharma Gmbh |
Anticuerpos para AXL
|
ES2483942T5
(es)
|
2007-12-14 |
2017-02-06 |
Novo Nordisk A/S |
Anticuerpos contra NKG2D humano y usos de los mismos
|
SI2391650T1
(sl)
|
2007-12-20 |
2015-03-31 |
Xoma (Us) Llc |
Postopki za zdravljenje protina
|
CA2709354C
(en)
|
2007-12-21 |
2014-06-17 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
NZ586828A
(en)
|
2008-01-15 |
2012-12-21 |
Abbott Gmbh & Co Kg |
Powdered antibody compositions and methods of making same
|
BRPI0908508A2
(pt)
|
2008-01-24 |
2016-03-22 |
Novo Nordisk As |
anticorpo monoclonal nkg2a anti-humano humanizado
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
CA2722600C
(en)
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
EP2172485A1
(de)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Neuartige Anti-CXCR4-Antikörper und ihre Verwendung bei der Krebsbehandlung
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
MX347291B
(es)
|
2009-03-20 |
2017-04-17 |
Amgen Inc |
Inmunoglobulinas portadoras y usos de las mismas.
|
MX338969B
(es)
|
2009-03-20 |
2016-05-06 |
Amgen Inc |
Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
|
EP2246364A1
(de)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Antikörper gegen CXCR4 zur Behandlung von HIV
|
US9200065B2
(en)
|
2009-07-03 |
2015-12-01 |
Bionor Immuno As |
Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain
|
EP2287336A1
(de)
|
2009-07-31 |
2011-02-23 |
Exhonit Therapeutics SA |
Verfahren und Methoden zur Alzheimer-Diagnose
|
US20120231013A1
(en)
|
2009-07-31 |
2012-09-13 |
Black Roy A |
Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
*
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2308897A1
(de)
|
2009-10-09 |
2011-04-13 |
Pierre Fabre Medicament |
Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
|
CA2781532A1
(en)
|
2009-11-20 |
2011-05-26 |
Amgen Inc. |
Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
|
JP2013511281A
(ja)
|
2009-11-23 |
2013-04-04 |
アムジェン インコーポレイテッド |
単量体抗体Fc
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
EP2371863A1
(de)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
|
EP2558497A2
(de)
|
2010-04-15 |
2013-02-20 |
Amgen Inc. |
Menschlicher fgf-rezeptor und beta-klotho-bindeproteine
|
US9457079B2
(en)
|
2010-05-12 |
2016-10-04 |
The Trustees Of Columbia University In The City Of New York |
Methods for producing enteroendocrine cells that make and secrete insulin
|
US8735548B2
(en)
|
2010-06-30 |
2014-05-27 |
Amgen Inc. |
Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
|
WO2012021648A1
(en)
|
2010-08-10 |
2012-02-16 |
Amgen Inc. |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
JP2013537425A
(ja)
|
2010-08-16 |
2013-10-03 |
アムジエン・インコーポレーテツド |
ミオスタチンに結合するポリペプチド、組成物および方法
|
JP6173911B2
(ja)
|
2010-09-10 |
2017-08-09 |
メディミューン リミテド |
抗体誘導体
|
EA201370076A1
(ru)
|
2010-09-22 |
2013-08-30 |
Амген Инк. |
Иммуноглобулины-переносчики и их применение
|
AU2011322508A1
(en)
|
2010-10-27 |
2013-05-02 |
Pierre Fabre Medicament |
Antibodies for the treatment of HIV
|
CN103492575A
(zh)
|
2011-01-18 |
2014-01-01 |
安姆根有限公司 |
NaV1.7敲除小鼠及其用途
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
DK3138581T3
(en)
|
2011-03-17 |
2019-04-15 |
Univ Birmingham |
REDIRECTED IMMUNTERY
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
BR112013030958B1
(pt)
|
2011-06-03 |
2022-02-08 |
Xoma Technology Ltd |
Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
KR102091294B1
(ko)
|
2011-10-26 |
2020-04-16 |
암젠 인크 |
Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
|
EP2589609A1
(de)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
US9717803B2
(en)
|
2011-12-23 |
2017-08-01 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
CA2864702A1
(en)
|
2012-02-22 |
2013-08-29 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
CN104411332B
(zh)
|
2012-03-30 |
2018-11-23 |
索伦托治疗有限公司 |
与vegfr2结合的全人抗体
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
EP2847219A1
(de)
|
2012-05-07 |
2015-03-18 |
Amgen Inc. |
Anti-erythropoietin-antikörper
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
EP2854850B1
(de)
|
2012-05-25 |
2021-05-26 |
Sloan Kettering Institute For Cancer Research |
Zusammensetzungen zur behandlung oder prävention von gi-syndrom und strahlungskrankheit
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
US10335482B2
(en)
|
2012-06-06 |
2019-07-02 |
Bionor Immuno As |
Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
|
CA2877573A1
(en)
|
2012-06-21 |
2013-12-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
EP2864358B1
(de)
|
2012-06-22 |
2019-08-07 |
Sorrento Therapeutics, Inc. |
Antigenbindende proteine zum binden von ccr-2
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
WO2014022102A1
(en)
|
2012-08-01 |
2014-02-06 |
Amgen Inc. |
Methods of using anti-apoptotic compounds to modulate one or more properties of a cell culture
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
PT2839860T
(pt)
|
2012-10-12 |
2019-07-29 |
Medimmune Ltd |
Pirrolobenzodiazepinas e conjugados das mesmas
|
EP2914630B1
(de)
|
2012-11-05 |
2021-03-03 |
Pierre Fabre Medicament |
Neuartige antigenbindende proteine und deren verwendung als adressierungsprodukt bei der behandlung von krebs
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
SG11201505960VA
(en)
|
2013-02-01 |
2015-08-28 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
AU2013381687A1
(en)
|
2013-03-12 |
2015-09-24 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びその結合体
|
CA2904337A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
WO2014202775A1
(en)
|
2013-06-21 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
WO2015010100A2
(en)
*
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
US10858426B2
(en)
|
2013-09-05 |
2020-12-08 |
Ab2 Bio Sa |
IL-18 binding protein (IL-18BP) in inflammatory diseases
|
JP6668241B2
(ja)
|
2013-09-05 |
2020-03-18 |
アムジエン・インコーポレーテツド |
予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子
|
EP3055695A1
(de)
|
2013-09-12 |
2016-08-17 |
Institut National de la Santé et de la Recherche Médicale |
Verfahren zur in-vitro-quantifizierung von alloantikörpern, autoantikörpern und/oder therapeutischen antikörpern
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
JP6621744B2
(ja)
|
2013-10-31 |
2019-12-18 |
アムジエン・インコーポレーテツド |
組換えタンパク質のグリコシル化を調節するためのモネンシンの使用
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
WO2015116315A1
(en)
|
2014-01-29 |
2015-08-06 |
Amgen Inc. |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
RU2685259C2
(ru)
|
2014-04-25 |
2019-04-17 |
Пьер Фабр Медикамент |
Конъюгат антитела и лекарственного средства и его применение для лечения рака
|
SI3134124T1
(sl)
|
2014-04-25 |
2019-06-28 |
Pierre Fabre Medicament |
Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
|
JP6835591B2
(ja)
|
2014-04-25 |
2021-02-24 |
ピエール、ファーブル、メディカマン |
Igf−1r抗体および癌処置のためのアドレッシングビヒクルとしてのその使用
|
WO2015200901A1
(en)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
CN107148282A
(zh)
|
2014-08-22 |
2017-09-08 |
索伦托治疗有限公司 |
结合cxcr3的抗原结合蛋白
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
ES2900331T3
(es)
|
2014-10-15 |
2022-03-16 |
Amgen Inc |
Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
|
US20170233467A1
(en)
|
2014-10-17 |
2017-08-17 |
Amgen Inc. |
Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies
|
EP3034620A1
(de)
|
2014-12-17 |
2016-06-22 |
Diaxonhit |
Zusammensetzungen und Verfahren zur Diagnose von Schilddrüsenkrebs
|
FR3030758A1
(fr)
|
2014-12-19 |
2016-06-24 |
Inst Nat De La Rech Agronomique (Inra) |
Marqueurs diagnostiques de la maladie de crohn
|
CA2971288A1
(en)
|
2015-02-02 |
2016-08-11 |
The University Of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
|
AU2016219170B2
(en)
|
2015-02-13 |
2021-09-09 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CTLA4
|
EP3265491A1
(de)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
|
SG11201706879UA
(en)
|
2015-03-05 |
2017-09-28 |
Ab2 Bio Sa |
Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
|
US10167334B2
(en)
|
2015-04-03 |
2019-01-01 |
Xoma Technology Ltd. |
Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
|
US10214591B1
(en)
|
2015-04-03 |
2019-02-26 |
Alienor Farma |
Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
|
WO2016164669A2
(en)
|
2015-04-08 |
2016-10-13 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd38
|
JP2018515603A
(ja)
|
2015-05-04 |
2018-06-14 |
ビオノル・イムノ・アクシェセルスカプBionor Immuno AS |
Hivワクチン用の投薬レジメン
|
FR3036287A1
(fr)
|
2015-05-19 |
2016-11-25 |
Univ Bordeaux |
Traitement et detection des trypanosomes
|
AU2016304588A1
(en)
|
2015-08-06 |
2018-02-15 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
WO2017058944A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
AU2016344663B2
(en)
|
2015-10-26 |
2023-09-07 |
Pierre Fabre Medicament |
Composition for the treatment of IGF-1R expressing cancer
|
US10849906B2
(en)
|
2015-11-30 |
2020-12-01 |
Yanhui Xie |
Use of Akt2 in diagnosis and treatment of tumor
|
BR112018013268A2
(pt)
|
2015-12-31 |
2018-12-11 |
Progastrine Et Cancers S A R L |
composições e métodos para detectar e tratar câncer gástrico
|
BR112018013272A2
(pt)
|
2015-12-31 |
2018-12-11 |
Progastrine Et Cancers S A R L |
composições e métodos para detectar e tratar câncer esofágico
|
KR102507685B1
(ko)
|
2015-12-31 |
2023-03-08 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
난소암의 검출 및 치료를 위한 조성물 및 방법
|
US10118963B2
(en)
|
2016-01-29 |
2018-11-06 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
US11340233B2
(en)
|
2016-03-07 |
2022-05-24 |
Pierre Fabre Medicament |
Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
AU2017263454B2
(en)
|
2016-05-11 |
2023-02-09 |
Amgen Inc. |
Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
|
CA3030156A1
(en)
|
2016-07-07 |
2018-01-11 |
Iovance Biotherapeutics, Inc. |
Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
|
JP7148493B2
(ja)
|
2016-08-01 |
2022-10-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
副甲状腺ホルモン受容体1(pth1r)抗体およびその使用
|
AU2017335771A1
(en)
|
2016-09-28 |
2019-02-28 |
Musc Foundation For Research Development |
Antibodies that bind interleukin-2 and uses thereof
|
US20200023072A1
(en)
|
2016-10-11 |
2020-01-23 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
TW201829469A
(zh)
|
2017-01-03 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
包含抗4-1bb純系20h4.9之雙特異性抗原結合分子
|
EP3576789A4
(de)
|
2017-02-01 |
2020-11-25 |
Centrymed Pharmaceuticals Inc. |
Monomere menschliche igg1-fc- und bispezifische antikörper
|
ES2926532T3
(es)
|
2017-03-30 |
2022-10-26 |
Progastrine Et Cancers S A R L |
Composiciones y métodos para tratar el cáncer de pulmón
|
KR102317805B1
(ko)
|
2017-03-30 |
2021-10-27 |
이씨에스-프로가스트린 에스에이 |
전립선암을 검출하기 위한 조성물 및 방법
|
EP3398967A1
(de)
|
2017-05-04 |
2018-11-07 |
B Cell Design |
Antikörper gegen karzinoembryonisches antigen zur krebstherapie und -diagnose
|
CN111032694B
(zh)
|
2017-07-14 |
2024-03-08 |
辉瑞大药厂 |
针对madcam的抗体
|
EP3444272A1
(de)
|
2017-08-17 |
2019-02-20 |
International-Drug-Development-Biotech |
Behandlung von ck8-positivem krebs in verbindung mit dem k-ras-genstatus
|
WO2019046600A1
(en)
|
2017-08-30 |
2019-03-07 |
Amgen Inc. |
INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE
|
CA3084687C
(en)
|
2017-12-05 |
2024-01-02 |
Progastrine Et Cancers S.A R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
EP3502140A1
(de)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ecs前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
AU2019228339A1
(en)
|
2018-02-27 |
2020-09-10 |
Ecs-Progastrin Sa |
Progastrin as a biomarker for immunotherapy
|
US20220111065A1
(en)
|
2018-05-23 |
2022-04-14 |
Adc Therapeutics Sa |
Molecular adjuvant
|
CN112424228A
(zh)
|
2018-07-04 |
2021-02-26 |
豪夫迈·罗氏有限公司 |
新型双特异性激动性4-1bb抗原结合分子
|
US12011485B2
(en)
|
2018-09-27 |
2024-06-18 |
Pierre Fabre Medicament |
Sulfomaleimide-based linkers and corresponding conjugates
|
WO2020065096A1
(en)
|
2018-09-28 |
2020-04-02 |
Pierre Fabre Medicament |
New immunocytokines for the treatment of cancer
|
EP3897851A2
(de)
|
2018-12-17 |
2021-10-27 |
Revitope Limited |
Doppelimmunzell-engager
|
JP2022531113A
(ja)
|
2019-04-30 |
2022-07-06 |
ギガジェン,インコーポレイティッド |
組換えポリクローナルタンパク質およびその使用方法
|
US20200362057A1
(en)
|
2019-05-16 |
2020-11-19 |
Snake River Bioscience, Inc. |
Compositions and methods for the treatment of major depressive disorder
|
US20220227888A1
(en)
|
2019-06-07 |
2022-07-21 |
Amgen Inc. |
Bispecific binding constructs with selectively cleavable linkers
|
TW202115124A
(zh)
|
2019-06-26 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
結合至cea之新穎抗原結合分子
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
US20210221886A1
(en)
|
2019-12-05 |
2021-07-22 |
Sorrento Therapeutics, Inc. |
Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
|
JP2023513059A
(ja)
|
2020-01-31 |
2023-03-30 |
ザ クリーブランド クリニック ファウンデーション |
抗ミューラー管ホルモン受容体2抗体及び使用方法
|
CN115485300A
(zh)
|
2020-02-26 |
2022-12-16 |
索伦托药业有限公司 |
具有通用掩蔽部分的可活化的抗原结合蛋白
|
WO2021195089A1
(en)
|
2020-03-23 |
2021-09-30 |
Sorrento Therapeutics, Inc. |
Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
|
EP3889183A1
(de)
|
2020-04-01 |
2021-10-06 |
Pierre Fabre Medicament |
Proteinkomplex mit einem immunzytokin
|
WO2021217083A1
(en)
|
2020-04-24 |
2021-10-28 |
Sorrento Therapeutics, Inc. |
Memory dimeric antigen receptors
|
AU2021258279A1
(en)
|
2020-04-24 |
2022-11-10 |
Vivasor, Inc. |
Lateral flow device for detection of neutralizing antibodies against SARS-CoV-2
|
AU2021283933A1
(en)
|
2020-06-04 |
2023-01-05 |
Amgen Inc. |
Bispecific binding constructs
|
WO2021253002A1
(en)
|
2020-06-12 |
2021-12-16 |
Gigagen, Inc. |
Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
|
CA3183034A1
(en)
|
2020-06-26 |
2021-12-30 |
Heyue Zhou |
Anti-pd1 antibodies and uses thereof
|
IL299289A
(en)
|
2020-06-26 |
2023-02-01 |
Sorrento Therapeutics Inc |
Oncolytic herpes simplex viruses (HSV) expressing immunomodulatory proteins
|
AU2021303508A1
(en)
|
2020-07-10 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
TW202233660A
(zh)
|
2020-10-30 |
2022-09-01 |
美商安進公司 |
過表現胰島素樣生長因子受體突變體以調節igf補充
|
EP4241085A1
(de)
|
2020-11-04 |
2023-09-13 |
Sorrento Therapeutics, Inc. |
Lateralflussvorrichtungen zur hochempfindlichen detektion einer coronavirusinfektion und verfahren zur herstellung und verwendung davon
|
MX2023006573A
(es)
|
2020-12-03 |
2023-06-19 |
Amgen Inc |
Constructos de inmunoglobulina con multiples dominios de union.
|
KR20230131204A
(ko)
|
2021-01-12 |
2023-09-12 |
에프. 호프만-라 로슈 아게 |
암 세포에 결합하여 방사성핵종을 상기 세포에 표적화하는분할 항체
|
JP2024503654A
(ja)
|
2021-01-13 |
2024-01-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
併用療法
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
US20240181073A1
(en)
|
2021-03-03 |
2024-06-06 |
Sorrento Therapeutics, Inc. |
Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
|
JP2024513172A
(ja)
|
2021-03-26 |
2024-03-22 |
ヤンセン バイオテツク,インコーポレーテツド |
対らせん状細線維タウに対するヒト化抗体及びその使用
|
CA3221925A1
(en)
|
2021-06-09 |
2022-12-15 |
Sorrento Therapeutics, Inc. |
Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
|
TW202328442A
(zh)
|
2021-09-10 |
2023-07-16 |
美商安進公司 |
平臺宿主對igf—培養基之適應
|
WO2023154305A2
(en)
|
2022-02-10 |
2023-08-17 |
Amgen Inc. |
Antibody protein product expression constructs for high throughput sequencing
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
TW202345899A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(三)
|
WO2023170290A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
TW202400636A
(zh)
|
2022-03-11 |
2024-01-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(一)
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|